Drugs / EC17
last change Nov 2014 re-read 2 minutes ago

EC17

Other / unclassified

Developed for
renal cell carcinoma · cancer
Investigated by
University of Pennsylvania · Endocyte · Mayo Clinic

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01778933 May 2013 → Sep 2014 renal cell carcinoma University of Pennsylvania Completed No outcome recorded
Phase 14 trials
Phase 1 NCT01994369 May → Nov 2014 female breast carcinoma University of Pennsylvania Completed No outcome recorded
Phase 1 NCT02000778 Nov 2013 → Nov 2014 ovarian carcinoma University of Pennsylvania Completed No outcome recorded
Phase 1 NCT01996072 Nov 2013 → Sep 2014 primary hyperparathyroidism University of Pennsylvania Completed No outcome recorded
Phase 1 NCT00329368 Sep 2005 → Dec 2007 cancer Endocyte Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01511055 Jan 2012 → Jun 2014 ovarian carcinoma Mayo Clinic Terminated No outcome recorded
Phase 2 NCT00485563 Jun 2007 → Aug 2008 renal cell carcinoma Endocyte Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as EC-17 “Folate-fluorescein isothiocyanate, or folate-FITC, also identified as EC-17, targets folate receptors over expressed in certain cancers such as breast cancer, and could help in...” NCT01994369
7

“The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators...” NCT01996072

NCT01994369

NCT01511055

NCT00485563

NCT01778933

NCT02000778

NCT01996072

Known as EC17 (Folate-FITC) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00329368
Known as Folate-FITC “A fluorescent contrast agent (folate-FITC or EC17) will be used to determine if it will localize to the primary tumor nodule(s) or mass(es) of patients undergoing parathyroid surgery.” NCT01996072
1

“EC17 (Folate-FITC)” NCT00485563

Known as Folate-fluorescein conjugate ChEMBL registry synonym — accepted as the source's own label CHEMBL4297279
Action Deplete “mark it for destruction by the body's immune system” NCT00329368
Modality Other / unclassified “a drug made by linking folate (a vitamin) with FITC” NCT00485563
Route Subcutaneous “administered subcutaneously” NCT00329368